EBV
0 - 14 !
" #
$% & '(
)
* ( , - ./
-1
-2 3
! "#
Epstein-Barr virus :
!"#
$ % & ' (
) * + % , -# ./ % 0"1 "
2 2 3#2 4 ' 3#
(
!5 6"1 )' 7 12
+ 8 5 ) 1
# 9 3 1 : -
! % *% , ) "
1 ; " < 12 = #
>
&
" # ? *1
& @ # + $ A
1 1B C#2 1D E / F 9EBV
" 1G ) / 1?
? 5 H#D * ! % 0"1 " )
0 - 14 '
# K .
% : / F ) M - 9 /FN O ' 3 "#P % 1384
O ' ! + 1385
9 , / 1 !
3#
1TM <1.E ! 3 U %
) 6 (
! #2 )' ) X 5 0 - 14 9 O '
# ?G18 % 1Y / F % .
K , )
! ),D
$ ,Z
3# ' < *" E 4'1+ ! ,
9
! - , [
# ?G18 (
! [ [ \"% 3 ?' , ) %
? 5 H#D *
EBV (VCA- IgG)
*1 8 3 #
# 18 . 3 K1 3 ?' 2
SPSS% [G *% 5 ! 5 "
Chi-Square
]F' %
/
*%
05 /
P 0
# ?G18 % 1Y $ P " [ % .
% : 6 , 245 `
# ?G18 % 1Y a NP % .
9 #/ ) 138 1b+ 1 ) 3 / 56 (%
"
107 1?- 1 ) 7 / 43 (%
(#
' ) U ,
2 07 /
±3 72 / 4
% - #/ ) U " O ' 8
/
±1 2 / 5 1 . 2 / 81
% 9 1G ) " fg 1? * % 11
%
* %
# 1?
( 8 / 7
% [
# ? 1?
(
? 5 1?
% * / <" h "
# *%
( a NP ) i ? ! 4
)' j [G 9
? 5 1?
EBV#D * j [G
# ) 04 / 0
P= ( ) l,2 (
% - #/ j [G 9
#D * ? 5 1? ) U
j [G EBV
! 4 ) 001 /
P<0 9 41 /
r=0 (.
?G : ) * 2
9a NP
EBV 6 % 9!
2 / 81
%
# 8# [ " )' j [G
3 - % j [G ) U ) /, 1+ * 2 #
,? * X' , % 0"1 " % -1 j [G $ " #
< / F 1 ' K $P 1 m ! #2 % 6 # no4 9 4 < / F % 5 #
$
" % - /, ! m +
# ! Z ) % #X ]F' ! )
.
% ) ?4+ 0"1 ": (
(
? 5 1?
0"1 " * (
!"#
-345 67 % &8 . 9 )
% 14
% .3 : 4 :
; <
= ( 1386 (
A B : 14 / 9 / 1385 B G H1!
: 2 / 12 / 1385 J BK5 : 28 / 1 / 1386
3"18 % ?' (! * X % , npo q G (O"Ab 3# b 1
Z [+ 3#Z4 ! * X % , 5
. "
NP [ 1
! " ! ' < N
! #2 Z [+ K 3 U4 0% 5 :
! #2 -
* 5 s -
1TM ! ?'% ,
) 6 ( -
?b+ # 43353 - 98136
) : 09151411880 Z "1?Z b+
! 1 ! - O N? ! ' , <u 2 . ( 2 U4 5 K * 1? 2
, & [+ 3
) ?4+ 0"1 "
-
(EBV)*% 9
% ) " * 1 36
O '
3# 3 4 G $fY
% K
# 5 ' . )
0"1 "
[ , 3 5 h+ " 3 3# 1 " h+12 3 - "
!
!# % 1, K , * 1 1G 1G
Y
# .
$N? ! 2 < P 1 0 , a 1 ' )Z, "
'
B * 2
% N E * X4o -
) " 2
# 1 8% ! Z
) 2 (.
" 8% -1 ) ' % 1?4 0"1 " ) *1 8%
s%
#2
"
"1 4 "
* 2
M p?- 1 ; 9
8% -1 " ! %" * X? 1U
$ Y G b q 1?
) 1 - 3 .(
<% M
>
&
1?4
8%[ % b n o4 $ Y
# ) 1 (.
3 14? ! X 1' 1' % 0"1 " ) *% ,
"
* p?Y /D"
9 v)' " ,?
% , u 3#, 1 B
% *
"1 " *% , * ?
% ( 8 ) + )' *
9
/' * 2% 4 % 8#
/, 1+ a % " ?G
j [G % ?G14 + * 2% 4
% b *% , 6 A
1B
# ) 49391 (.
v & EBV
H X
K w po K
%
! %
# ) 69593 ( ( ) l,2 K
TO ' '% "
K
"
G x % 1? # K " O [ *
\% [8 0"1 " ) ' 3#
) 795 .(
y% " !# K , % % 4? % Y 0"1 " ) 8% + # P
& ?' +5 , 5 "
9
& ? ,2 , 5 9
+"1 " + ? ' f 1 9
& @ "% * X % , 9
b 9
f Y 9
*
*#f "
# ) 893 (.
2 )
0"1 "
9 ) + ) ' *% ?G18 %
" ) ' ) % *% , n o4 % M p?- 1 ; $ Y % b " X y% ) l,2
#
* 1
< E 31 o [ 5
# [ 9 X *% , 0% " n o4
*Epstein-Barr virus
' ,2 [ E % b y% ! % " *1 8 .
1' 1' % : ?o 3# K < / F 9
# "
"
' % b ! b !
) 3 9 9 - 11 ( (
*%
% Y 0"1 " ) '
90
% 1G
# , 3 5 %
) 392 (.
)
!"# 1G % < fB ,2 " "%
0"1 " ) 9
1D E / F ) / C#2
1? " 1G
? 5
EBV * 9 1G ! 3 5 4
# 9
%
! 0 - 14 ' / 1
# 3
<1.E 3 U %
1TM ) 6 (
! #2 1X
# K .
$ %& '()
% M / F ) K /FN <% M
9#
! 0 - 14 ' O ' )
1384 + O ' ! 1385
3 U % 1TM ! ?'% , !
) 6 ( / 1 ! #2
# ?G18 % 1Y '%1 % 9# 1 .
4'1+ < *%"5 18 % [
*
< *" E
% )
" % - #/ 9h 9)' ....
?G 2 U4 5 * 2 (
),D % (# $ ,Z 9 1G ) * 1 , &
! -
# ?G18 [ .
/ 1 % ! % , ! )
! 8#
?G !"# ,/
* 1 M p?- * 2
# EBV
.
N * % " # # * X % , ?f ! % , n
, 9
H# * X % , 3# ?- % ) l,2
) [ *
% "
# #4 a NP .
, , 5 2 " $N? ! - O N? ! ' 3 U4
# 18 [ 1G " # K1' (
% 6 , 1
%
*"
245
,
\"%
" [
Diasorine z' 1?
? 5
*
EBV-VCA-IgG
{ O P
450 - 630 1?
3 #
# *1 8 .
q G 0 ' 1
9 1 m 1?
IU/mL
11 9 ) " fg
IU/mL
11 - 9 1 "
IU/mL
9
?G18 1= % .
3
|, * 2 3 ?' 3# *%"5
K1
*% 5 % [G
"SPSS Chi-Square! 5
/ ]F' %
*%
05 /
P 0
# ?G18 % 1Y $ P " [ % .
* + : 6 , % 245
` (# ?G18 % 1Y % % )
#/
138 1b+ 1 ) 3 / 56 (%
"
107 1?- 1 ) 7 / 43 (%
# .
)' ) U
! 07 /
±3 72 / 4 O ' . ) U v '
%
! 1?- 1 /
±3 49 / 4
"
%
! 1b+
1 /
±3 9 / 4 O '
<"
/
*%
# ? # 2 .
1 ! }1 ) % 3#
H * %
% - #/
8 /
±1 2 / 5
# 1 .
? 5 1? ) U *
v$ %
IU/mL ! 04
/
±72 35 / 57
# ) /
) (
! [
! 1b+ %
IU/mL
04 /
±74 7 / 60
"
%
! 1?-
IU/ML
29 /
±68 1 / 53 ( C ?- 1=
*% 5
/ f % .
! v$
! j 5 ~' + 9 199
1 ) 2 / 81 (%
9 fg 19 1 ) 8 / 7
% (
"
27 1 ) 11 (%
"
/ *% 5 • f %
*%
6 1=
* X2"18 % EVB
v '
#4 3#2 4 : ?o .
v)' )
1 1G
? 5 1? " }1 % 3#
*
/ • f %
? 5 1? )' j [G " " *%
*
j [G ! 4 ) 04 / 0
P= ( ) 28 / 0
r= ( )
% , 1 ( (
• f % )
h " 12 %
#2 4 3
# ( j2"x+ ) % ) l,2
% - 1G #/ j [G # no4 9
) U 1?
? 5 j [G * #
) 001 /
P<0 ( 9 ) 41 / 0
r= ( )
% , 2 ( (
# h f % U?b " ) .
-%.
h+12 8 & EBV
0"1 "
h+12 3 - "
' 3# 1 "
) 291 (
"
8 5 9!5
1
!# ) [U
!# % 0"1 "
< P 1 " ! 2 a 1 "
' O N? $ Y 2 " N E )
392 .(
< ,? " /' O E % * 2% 4 % EBV
€m ,/ ?G14 + * 2% 4 # b $ " " 8% -1 %
s% ! %"
?/ M 1 ; /, 1+ | % #2
[ 3 / 1
% %
H
3# • $ " "
' 1?/ % b % [ E ) %
) 3 ( ( ) 1
* #? % *% , "1 ) 1?4 G18 ? ! • 1- " % 6 ) 1?4 "
*1 8% #
j 90
% ' 3 1,2 ) T (
2 O E 1
% * 2% 4 %
/' O E 9
2 *% , 6 2 " {"
) + ) ' % 1
# ) 893 .(
3%"
? X % *% ,
! 7 - 10 ) T % " "%
20 - 60
"%
' % "
+ ) '
& <% M X !"# ; )
% G x ' : - )
593 (
! %
% 75
%
%
*% ,
"1 $Z
# ) 4 (.
!"
1 -
% & ' ( )(
* ! '+ (
,- ) !
!"
2 -
% & ' ( )(
* ! ! / ,( ( ,- ) ! AGE
14.00 13.00 12.00 11.00 10.00 9.00 8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 .10 .00
MeanAB
90 80 70 60 50 40 30 20 10
% 50
%
*% , 1 % <% M
9 +
"
3# x % G
) 493 (.
# % 1 '
>' >2
" U
?+
% K 4
80
%
! % ,
\% [8 3#
) 4 ( 1?Z "
9 47 C 1 K 2
9
"1 f , 5 " + ? '
& ?' +5 9
% 9 3% ) 8 K"%# ' 9
b
"
4 1U x?
# ?b2 *% , y% " 2 )
8959493 .(
| '" : 4 "
2 9
" X 5 ! M p?- 1 ;
% *% , ) 3x ! %" % ! ? X
$ Y 1 ; ! %" * X? 1 '
?G q 1 ' ) 893 (.
) "1+ Z 8 a 1 0"1 " ) 220
/ 340 [
"
4;
*
!5 4 + , >, ?b ' #
! 9 '
* 2
$p? hZ "1' " 2 K ? + 9B
" "
% ' $- 1 gZ "
[ X % " #
O ' (
E1 ) % !"# #
# "
" %" * X?G E1 ) h+ # x % G O "# Z % G
# % 4?
.
O ' # % " 1 gZ
B * 2
EBV 3 5 3 1,2
O '
T* 2 j "
*% , % 3# 2
# * X?G 8%[
.
O % 2 , 9
" m , *% , ? O f
$M E $
) 1 (
% % b
' (
? 5
[ 1 *
* 0"1 " : ?o (
) 1U C1
#/ j [G 4 " %
O '
' * 2
1?4 T
6 1U 1' T
$ N % ' 6 G X % " # jN [ E EBV
# ) 8 (.
E1 H E
| 1' ~' + *% ,
"IgM IgG
~' + " % K , % VCA
IgG
% EA
3 1,2 % ;
# .
~' + IgM
%‚8 ; VCA
H#E ' * 1 $Y
% X7 Y ? 2
# .
IGg ~' +
VCA H E 3%" 1- " % [
1g #E
?G j2 3 # 7 ? 2 # 7 y1 % h>' " 3# '%
9
H#E % 1, 1-5 h>'
% $ Y 3# Y ? B '
.
? 5
*
EBVA* 2 i %#? " * X? %
y1 % 3
- 4 12 ƒ *% , 6"1 h+ 3 % "
F' } Y 1, K , * 1
# (
! #NG ) 1
? 5
EBVA * E %
? 5 1 '
* 2
# % "
9
! 4
' 1 - 3# 2
. 3 #
IgM *1 8
VCA
M p?- " ) 1? % ) 1
! 5
"1' Z @
* 1
H E n o4
* 1 " 3 EBV
G n o4 #
' .
*% , n o4 %
! 5 EBV
? 5
$ G"1?2 *
)
? 5
* O + * 2 -
$ ( 90
IMN% %
" ) T " !
j 50
%
1 %
% X7 no4 % O ' '
.
<% M %
!
! 5 & " q G
9EBV
K
* X4 5 M p?-
K m EBV
' %
# 3 ] D m (
) X4 5 " fY < fB * 1
# 3# 5 #/?' ) /
# .
%
"1 • f % ]F' % 3# K : ?o < / F )' *% , 9
% o * p?Y /D" " /,
' ?G18 % 1Y .
/ F %
*"% $ 1 % * 283
`
) ' ) ! "
1 - 23 G1 ‚+ <% M O ' 9
6 54
%
? 5
EBVA #D *
"
71
%
VCA H#D $ Y (
G ) 3 - % 6 " 1? j [
% * 2
5
# 9 /, 1+
+ ) ' % "
) 1 1 U,47 1 )
9 (
$M E i ?
/ F 1D E [ A b ) # u
# .
O ' % / F & % 1969
z'
Henles
"
z' 4 %
Collesgu
"
Kafvleo
G1 ‚+ K 9
j # 18 no4 90
%
! 5
H % N 1G
? 5 * % ! %"
fg *
# ?b2 EBV
) 8 .(
? 5 ]F' *1U / F %
EBV * ) %
" 1 ! 5
3 % 1Y '%1 % ,
9 3"18 %
' ) 1 - 5 O ' 9 70
%
? 5 * % 2 1
# fg *
(
E % v ' 3"18 %
X 4 56
% , 5 !
1?
# ? * ? 5 fg )
11 (.
? 5 1? b N %
EBV *
% !
' 3"18 " ) Z7 2 K ?f )
#2 (
%
" &7
# K '
9
* 21?
IGg
"VCA EA
3"18 %
#2 ) ' 1G (
*1 U,47 P # 18 G
b )
u
*% 8 ' !"# 1G % "
% ) 6 ( / F "
1D E , B % ? ) [ .
# '% K # % *1U / F % 9
6
) 1G %
4 / 68
%
# 18 1 „ )
12 ( ( )
fb / F % 1D E
2 / 81
% (
"
% % <" )
, 3 P % ! G *1 8
( ) ) l,2
/ F K $P F
1D E % [ 1 &
, 1 ! ?' ]F' 2 ?'"% " 21X *
#X ]F'
7
" ` #/ " ' ! #
3 -
/, 1+ * 2
# i ?
! # 7
%" 2
b % =?
( 2 1
) + ) ' % *m 6 O E
3 - % "
% ]F' " /, 1+ * 2 5
# K# "
/ F % h " ) <"
1D E
" # 5 '
€ 12 ƒ ! % , ; % 0"1 " #D fg 1? ) l,2 '
!"#
? X *% , M p?-
% *% , !
! 4 ) + ) ' %
#2 9
? ,
) 8959493 (
"
<m N )
11910999291 (
" ? $ o,2
j2 " | 1' n o4 % % *% , ,2 y%
hZ/ *% , '
.
/ 0
?G
) * 2
9a NP 6
% EBV
9!
"#E 2 / 81
% #
" )' j [G
3 - % 8# [
j [G ) U ) /, 1+ * 2
#
* X' , % 0"1 " % -1 j [G $
,?
9 4 < / F % 5 " #
K $P 1 m ! #2 % 6 # no4
F 1 '
$ # < /
/, ! m
" % - +
# ! Z ) % #X ]F' ! )
.
1. 2 :
1- Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000; 343 (7) :481-92.
2- Nicholas JB. Monononucleosis and Epstein-Barr virus infection [emedicine web site] May, 23, 2006. Available From: www.emedicine.com,Accessed/11/22/2006
3- Har BJ. Epstein-Barr virus. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson Textbook of Pediatrics.
17th ed. Philadelphia: WB Saunders; 2004.
4- Cohen JI. Epstein-Barr virus infection including infectious mononucleosis. In: Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw Hill; 2001:
1109-1111.
5- Feigin RD, Cherry JD. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia; WB Saunders; 2004.
6- Roubalová K, Weinreb M, Roubal J, Kodet R, Koutecký J, Vonka V. Epstein-Barr virus (EBV) antibodies in children with non-Hodgkin's lymphomas. Acta Virol. 1988; 32 (4): 339-48.
7 - f M .
! 1 % * X % , .
! 1X 1X7 ( : 1372 . 8- Belshe RB. Textbook of Human Virology. 2nd ed. St- Louis: Mosby; 1990.
9- Figueira-Silva CM, Pereira FE. Prevalence of Epstein-Barr virus antibodies in healthy children and adolescents in Vitória, State of Espírito Santo, Brazil. Rev Soc Bras Med Trop. 2004; 37 (5): 409-12.
10- Chan KH, Tam JS, Peiris JS, Seto WH, Ng MH. Epstein-Barr virus (EBV) infection in infancy.J Clin Virol. 2001;
21 (1): 57-62.
11- Alebouyeh M, Peller P, Goetz O, Ameri MA. Comparative study of the prevalence of Epstein-Barr virus infections in Iran and Germany. Monatsschr Kinderheilkd. 1984; 132 (11): 850-51.
12- Pancharoen C, Bhatrarakosol P, Thisyakorn U. Seroprevalence of Epstein-Barr virus infection in Thai children. J Med Assoc Thai. 2001; 84 (6):850-54.
Title: Frequency of Epstein-Barr virus (EBV) anti-antibody titer in 0-14 year old children referred to Aliasghar clinic in Zahedan
Authors: Gh. Soleimani1, E. Saneei Moghadam2, F. Gorgani3 Abstract
Background and Aim: Epstein-Barr virus (EBV) infection produces a wide variety of clinical symptoms ranging from an asymptomatic infection to the classic infection "mononucleosis". Clues of the virus have also, been found in some malignancies. Since the lower the age at infection onset, the weaker the clinical symptoms will be; the disease can be asymptomatic and atypical in children. Regarding epidemiologic factors affecting EBV infection, the present study was carried out to determine the frequency of EBV anti-antibody titer in 1- 14 year old children.
Materials and Methods: In this cross-sectional and descriptive study, which was done between 2005 and 2006, all 0-14 year old children who had been referred to Aliasghar Children Clinic in Zahedan were surveyed. Questionnaires covering individual information queries were filled out for all children and their blood samples were taken. By using ELISA the amount of EBV anti-antibody (vcA-IgG) in the samples was measured. Finally, the obtained data was analysed by means of SPSS software using chi-square statistical test; and P 0.05 was taken as the significant level.
Results: Out of 245 cases under study, 138 cases (56.3%) were males and 107 cases (43.7%) were females. Mean age of the subjects was 4.72±3.07 years and mean family members was 5.2±1.8. Most (81.2%) of the cases revealed positive titer, 11% had negative titer, and 7.8% were intermediate after excluding less than one-year old children from the study -because of their inborn antibody- the result in percentage terms was 81.3%, 11.1%, and 7.6% respectively;
which did not reveal a significant difference with the previous stage .Antibody titer in both sexes was not significantly different.
Conclusion: Regarding the findings of this study, total prevalence of EBV infection among children is around 81.3%, which increases with age and living in large families. With respect to available statistics previous similar studies it revealed that the incidence of the infection in Zahedan was more than other sites, probably due to familial overpopulation and low level of hygiene
Key Words: Epstein Barr virus; Infectious mononucleosis; Asymptomatic infection; Anti EBV Ab titer
1Corresponding Author, Assistant Professor, Department of Pediatric, Faculty of Medicine, Zahedan University of Medical Sciences.
Zahedan, Iran [email protected]
2PhD in Laboratorial Sciences
3Physician
